Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Luye Bids to Acquire France's Ethypharm in Deal Worth up to $900 Million

publication date: Mar 31, 2016
Luye Group, the parent of Luye Pharma, is bidding to acquire Ethypharm, a privately held French pharma, at a price that could be as much as $800-$900 million. Luye faces competition on several fronts for control of Ethypharm, which is currently owned by PE firm Astorg Partners. Other investment companies are interested, as is the UK's Mundipharma, as well as several unnamed China pharmas, according to Bloomberg, which broke the story. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China